Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

djustments Adjusted Net sales $290,271 $- $290,271 Costs and expenses: Cost of sales 56,534 (4,189) (1) 52,345 Selling, general and administrative 115,002 (3,278) (2) 111,724 Research and development 33,582 (6,450) (3) 27,132 Operating income 85,153 13,917 99,070 Interest income, net (9,265) - (9,265) Other expense, net 282 - 282 Income before income taxes 94,136 13,917 108,053 Income taxes 34,608 5,239 (4) 39,847 Net income $59,528 $8,678 $68,206 Diluted earnings per share $0.44 $0.51 Diluted weighted average shares 134,652 134,652 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude amortization of commercial intangible assets related to marketed products. (2) To exclude separation costs. (3) To exclude upfront and milestone payments to partners. (4) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.

For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.


         Reconciliation of Projected GAAP Diluted Earnings Per Share to
                 Adjusted Diluted Earnings Per Share Guidance

                                                         Year Ended
                                                      December 31, 2009

    Projected GAAP diluted income per common
     share       
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Based in St. Louis, Missouri ... shirts for a couple of months now and are ... release, which reads “I’m not misbehaving, I have Autism, please ... parent’s of an autistic child in order to start a ... Not only are they raising awareness through the autism awareness ...
(Date:5/29/2015)... Fort Washington, PA (PRWEB) May 29, 2015 ... Doc ” quiz-based learning in 14 medical specialties, now ... quiz includes a wide spectrum of rheumatology disorders ranging ... , Alfred Saint Jacques, editorial director of MDLinx, and ... are excited about the impact it will have on ...
(Date:5/29/2015)... PALMER LAKE, CO (PRWEB) May 29, 2015 ... a brand new addiction, substance abuse, and co-occurring ... Opening celebration and ribbon cutting for the general ... patients June 2nd. , The Recovery Village at ... hospitalization, and intensive outpatient programming, utilizing traditional and ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... 2015 Johnson & Johnson and ... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a ... his use of the antipsychotic medication. According to ... the third bellwether trial to involve male breast ... in Pennsylvania’s Philadelphia Court of Common Pleas, where ...
Breaking Medicine News(10 mins):Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
... The Quigley Corporation, (Nasdaq: QGLY ) , ... on Friday, June 12, 2009, the United States District Court for the ... of the challenges to the results of the May 20, 2009 shareholder ... elected to the Board of Directors of the Company. , ...
... Finds Upgrades Will Save Money and Improve Standard of Care ... Area Hospital will soon undertake $2.3 million in infrastructure improvements ... , , The improvements, which will be completed in ... which would pay for the project in 6.5 years. A ...
... 2009 Calcium and dairy products play major roles in ... bone mass is not achieved until the third decade of ... adequate amounts of calcium, protein and vitamin D found in ... life. In a study in the July/August issue of the ...
... Jerusalem, June 14, 2009 Research by a Hebrew University ... product that has been shown in clinical trials to be ... cells. The research, conducted by Prof. Avraham Hochberg of ... won for him first prize among faculty members for this ...
... ... donors can visit giftoflife.org/give, and enter the promotional code 2009CLEVE to get their $54 marrow cheek-swab ... (Vocus) ... year. Her only hope is a bone marrow transplant, but so far her family has been ...
... , SAN DIEGO, June 15 Amira ... data from its LPA1 receptor antagonist program on June ... Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona. ... the Phosphatidic Acid/Lysophosphatidylcholine pathway, which among other things is ...
Cached Medicine News:Health News:Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board 2Health News:Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board 3Health News:Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board 4Health News:Ceremony at Passavant Area Hospital to Launch Efficiency Improvements 2Health News:Ceremony at Passavant Area Hospital to Launch Efficiency Improvements 3Health News:Young adults not drinking enough milk 2Health News:Hebrew University research leads to advanced trials of new cancer treatment 2Health News:Cleveland Residents Lining up to Help Save a Life with Free Donor Kits 2Health News:Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference 2
(Date:5/29/2015)... , May 29, 2015 Invetech ... contract manufacturing, and Vaxxas , a biotechnology start-up ... have been named winners of the 2015 Good Design ... Instrument , an advanced technology platform to support needle-free ... was announced last evening at the Good Design Awards ...
(Date:5/29/2015)... , May 29, 2015  Haemonetics Corporation (NYSE: ... , Chief Operating Officer, will present at the JMP ... on June 23 rd , 2015 at ... access Mr. Davies, presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
(Date:5/29/2015)... INDIANAPOLIS , May 29, 2015  Eli Lilly ... AZN ) today announced that they have entered ... and preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint ... Lilly,s VEGF Receptor 2 antiangiogenic cancer medicine. The planned ... patients with advanced solid tumors. The Phase ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... ended June 30, 2011. Key Recent Highlights: ... data from the open-label phase 2 study of Arikace™ (liposomal ... patients with Pseudomonas lung infections Added ...
... 8, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (CMED) ... in-vitro diagnostic ("IVD") company, and Leica Biosystems, a division ... scientific instruments, today announced that they have established a ... automated FISH kits to be used on the Leica ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8China Medical Technologies and Leica Microsystems Announce Collaboration 2China Medical Technologies and Leica Microsystems Announce Collaboration 3China Medical Technologies and Leica Microsystems Announce Collaboration 4
... MOBEE headboxes are ... Xltek's line of portable ... with a robust new ... latest software, XLTEK's standard ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
... The ACCU-Beam® line of Surgical Microscope Accessories ... lenses, fiber optic cables, and fiberoptic retrofits. ... (US pat. no. 5,264,928) is the only ... 3CCD cameras on the same adaptor body. ...
Medicine Products: